Lixte Biotechnology Holdings has engaged the services of BioPharmaWorks LLC of Groton to enhance the value of its clinical candidate portfolio.

Dr. John Kovach, founder and president of Lixte, commented: “BioPharmaWorks brings exceptional expertise in virtually all aspects of drug development, ranging from drug design, synthesis, pharmacokinetics and metabolism to intellectual property law, biostatistics and predictive toxicology. The BioPharmaWorks scientific team will be working closely with Lixte management to bring their expertise to Lixte, just as Lixte’s lead compound, LB-100, is nearing completion of its initial studies in patients.”